RxDoctor Payments Data

Brian Favero, MD

Ophthalmology · Port Huron, MINPI 1639130024

Payments from drug & device makers

$2,806in general payments, 2019–2025

Across 94 payments — averaging $29.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$528
  • Amgen$409
  • Alcon$323
  • Bausch & Lomb Americas Inc.$283
  • AbbVie$267
  • Regeneron Healthcare Solutions, Inc.$235
  • plus $762 from 15 others

What the payments were for

  • Food & beverage$2,806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,806 in reported general payments places this provider in the 70th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$121,378
Medicare patients
302
Services billed
1,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$52,284
LumiganBimatoprost44$24,068
CequaCyclosporine37$20,411
RocklatanNetarsudil Mesylat/Latanoprost18$10,005
Cyclosporine16$9,160
Prednisolone Acetate87$5,040
SimbrinzaBrinzolamide/Brimonidine Tart17$4,981
Travoprost18$2,087
Timolol Maleate68$1,704
Ketorolac Tromethamine93$1,615
Latanoprost53$1,359
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat23$773
MoxifloxacinMoxifloxacin Hcl50$766
Brimonidine Tartrate37$682
Dorzolamide Hcl17$364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$267$76,35187 claims
Sun Pharmaceutical Industries Inc.Cequa$528$20,41137 claims
Aerie Pharmaceuticals, Inc.Rocklatan$17$10,00518 claims
AlconSimbrinza$323$4,98117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Port Huron

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →